The FY20 MRP Translational Research Award (TRA) supports hypothesis-driven, translational, high-impact research. The TRA mechanism encourages applications with mature research projects that specifically focus on critical scientific or clinical melanoma issues, which, if successfully addressed, have the potential to make a major impact. Important factors under consideration will be continuity of research, clinical applicability, and leveraging of clinical samples from clinical trials and/or biorepositories. The TRA supports identifying scientific outcomes, through rigorous, robust research, that are translatable toward treatment and/or preventive strategies. Proposed research should be mature and well developed. Research proposed should aim to accelerate promising findings toward clinical applicability and leverage research results to maximize impact. The TRA is not intended to study research into clinical utility of PD-1 in combination with other therapeutics, or studies utilizing established cell lines. Variety of DOD Melanoma research grants

The goal of this Funding Opportunity Announcement (FOA) is to advance surveillance science by supporting the development of new and innovative tools and methods for more efficient, detailed, timely, and accurate data collection by cancer registries. Specifically, the FOA seeks applications for projects to develop, adapt, apply, scale-up, and validate tools and methods to improve the collection and integration cancer registry data and to expand the data items collected. Applications must be built on partnership with U.S. population-based central cancer registries (a partnership must involve at least two different registries). Tools and methods proposed for development are expected to enhance the registry core infrastructure and, in so doing, expand the usefulness of registry-collected data to support high-quality cancer research.

The purpose of this Notice is to inform potential applicants of the special interest of the National Cancer Institute (NCI) in encouraging the submission of applications to either PAR-20-089 Biomedical Data Repository ( U24-Clinical Trial Not Allowed) or PAR-20-097 Biomedical Knowledgebase ( U24-Clinical Trial Not Allowed) FOAs, focused on the establishment of new, or continued development of established cancer data resources that use state-of-the-art and cost-effective technologies and approaches, and that are of high value to the broad cancer research community. This NOSI applies to applications for both data repositories and knowledgebases.

Through this Funding Opportunity Announcement (FOA), the NCI invites applications to support research in new and innovative cohort studies that identify clinical, lifestyle, genomic, and other factors that affect health outcomes (e.g., morbidity, mortality, quality of life, physical, social, and psychological outcomes) in cancer survivors. This RFA supports research that requires the creation of a new prospective cohort study of cancer survivors that addresses a gap in knowledge pertaining to the health of cancer survivors. Proposals must identify the scientific gap that the study addresses, which may include emerging treatments, less common cancer sites, and/or other understudied populations of cancer survivors with disparities. Sample size and proposed data collection must be driven by the scientific questions proposed and include information from the following five domains: 1) disease characteristics (e.g., type, stage), 2) individual survivor characteristics (e.g., comorbidities, SES, social connections, access to care measures), 3) treatment, treatment-related effects, and follow-up care (e.g. dose, adverse events, palliative care), 4) behavioral and lifestyle factors (e.g., diet, physical activity) and 5) quality of life outcomes (health related quality of life). These domains may represent exposures and/or outcomes, depending on the research questions, and should be measured at multiple timepoints, when appropriate. The UG3 Planning-Exploratory Phase focused on recruitment and data collection/utilization, and the UH3 Implementation Phase focused on completing the research agenda. Milestones to be accomplished in the UG3 phase for transition to the UH3 will be proposed by the PI, with approval by NCI, and must include a timeline for recruitment and show feasibility for data collection and analysis. Recruitment is not required to be completed in the UG3 phase, but reasonable progress should be demonstrated so that all aims will be completed in the UH3 phase.

The FY20 PCRP Health Disparity Research Award supports promising research ideas that have high potential to make a significant impact in eliminating disparities in prostate cancer incidence, morbidity, mortality, and survivorship. Applications for this award are encouraged to be relevant to one or more of the FY20 PCRP Health Disparity Research Award Focus Areas and must ed to the selected focus area(s). If the proposed project does not address one of the FY20 PCRP Health Disparity Research Award Focus Areas, the application must provide a description to justify how the project will nevertheless address a critical disparity-related need in the field of prostate cancer research and/or patient care. Applications are encouraged from a spectrum of disciplines, including but not limited to basic science, engineering, bioinformatics, population science, psycho-oncology, translational research, health care services

In pursuit of that mission, the organization is inviting applications for its AACR NextGen Grants for Transformative Cancer Research program. Through the program, grants of up to $450,000 over three years will be awarded in support of young investigators engaged in creative, paradigm-shifting cancer research that has not be funded through conventional channels. The proposed research must represent a highly innovative approach to a major challenge in cancer and have the potential to lead to groundbreaking discoveries in the field and transform our understanding of the tumorigenesis process and/or our ability to treat, detect, or prevent cancer. The research can be in any area of basic, translational, or clinical science, but at least one AACR NextGen Grant will be awarded to a breast cancer-focused project.

Two programs are combined in this competition: the Pew Scholars Program in the Biomedical Sciences and the Pew-Stewart Scholars for Cancer Research Program; both are intended for early-career research with an emphasis on interdisciplinary projects Who should apply: Early-career assistant professors with a research interest in biomedical studies or cancer studies

In November 2018, the Moore Foundation announced its Diagnostic Excellence Initiative, which aims to reduce harm from erroneous or delayed diagnoses, reduce costs and redundancy in the diagnostic process, improve health outcomes, and save lives. According to the foundation, twelve million Americans experience a diagnostic error each year, with diagnostic errors playing a role in an estimated 40,000 to 80,000 deaths annually in the U.S. In short, there is an urgent need to improve diagnosis; however, without an awareness of baseline performance and standards against which to compare performance, there is no way to measure improvement or to gauge the results of interventions. Despite a lengthy and growing list of clinical quality measures in health care, few existing measures address diagnostic performance specifically. The challenge of finding meaningful clinical measures for diagnosis reflects the complexity of the diagnostic process.

The goal of the intended FOA is to establish Study Sites for PRS Methods and Analysis for Populations of Diverse Ancestry to collaboratively generate and refine PRS for populations of diverse ancestry by integrating existing datasets with genomic and phenotype data for a range of complex diseases and traits. Together with a Coordinating Center (described in a separate FOA), grantees funded under the intended FOA will form a Consortium with the primary objectives of: 1) leveraging genetic diversity to develop methods and improve the applicability of PRS to predict health and disease risk across diverse populations, and for a broad range of health and disease measures; and 2) optimizing the integration of large-scale, harmonized genomic and phenotype data to facilitate collaborative analysis, dissemination of PRS-related data, and development of related methods and resources.

· Virtual Cancer Center Scholar Option: Supports independent, highly accomplished early career investigators (referred to as Scholars) to conduct impactful research under the guidance of an experienced cancer researcher (i.e. Career Guide). Presents an opportunity for Scholars to participate in the unique, interactive Virtual Cancer Center (VCC) focused on fostering the next generation of cancer researchers. This award provides intensive mentoring, national networking, and a peer group for junior faculty. Scholars are required to interact with the VCC Director, Deputy Director, and fellow Scholars in addition to their Career Guide. For more information on the Virtual Cancer Center refer to the FY20 Virtual Cancer Center Funding Opportunity.

The Virtual Cancer Center Director Award (VCCDA) mechanism is a unique, interactive virtual cancer center (VCC) focused on bringing together two established investigators (Director and Deputy Director) and up to nine early career investigators (Scholars) to interrogate the commonalities of cancer. Candidates for Scholars will apply to a separate funding opportunity (W81XWH-20-PRCRP-CDA). The Director and Deputy Director will catalyze the growth and professional development of the Scholars in collaboration with the Scholars' Career Guides, assess the progress of the Scholars, promote the cross pollination of different cancer disciplines, and facilitate communication and collaboration amongst all of the VCC members. The overarching goal of the VCC is to develop successful, highly productive Scholars in a collaborative research and career developmental environment. The VCC will provide intensive mentoring, national networking, collaborations, and a peer group for junior faculty. The VCC will give Scholars opportunities to operate in a collegial, highly dynamic, and cutting edge center to lead cancer research to a new frontier. It is the intention that through the VCC, collaborations will foster new growth in different cancers and spur an integrated cancer center to ensure the research advancements across different cancers.

Funds small, short-term studies on leading women's health concerns including cardiovascular disease, female cancers, the role of hormones in disease and stage-of-life health issues such as pregnancy and menopause

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications describing research focused on improving care and health-related quality of life for childhood, and adolescent and young adult (AYA) cancer survivors. Specifically, this FOA solicits mechanistic, observational, and intervention applications that focus on six key domains: (1) disparities in survivor outcomes; (2) barriers to follow-up care (e.g. access, adherence); (3) impact of familial, socioeconomic, and other environmental factors on survivor outcomes; (4) indicators for long-term follow-up needs related to risk for late effects, recurrence, and subsequent cancers; (5) risk factors and predictors of late/long-term effects of cancer treatment; and (6) development of targeted interventions to reduce the burden of cancer for pediatric/AYA survivors.

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications describing research focused on improving care and health-related quality of life for childhood, and adolescent and young adult (AYA) cancer survivors. Specifically, this FOA solicits mechanistic, observational, and intervention applications that focus on six key domains: (1) disparities in survivor outcomes; (2) barriers to follow-up care (e.g. access, adherence); (3) impact of familial, socioeconomic, and other environmental factors on survivor outcomes; (4) indicators for long-term follow-up needs related to risk for late effects, recurrence, and subsequent cancers; (5) risk factors and predictors of late/long-term effects of cancer treatment; and (6) development of targeted interventions to reduce the burden of cancer for pediatric/AYA survivors.

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) encourages grant applications for support of the core functions of Cancer Epidemiology Cohorts (CECs), as well as methodological research. This FOA is intended to support the maintenance of existing CECs infrastructure and resource sharing with broader scientific communities.

Elsa Uhinck Pardee was born on a farm south of Cleveland, Ohio, on November 7, 1884, and received her elementary education in a one-room school. She married James T. Pardee in 1914. A college classmate of Herbert H. Dow, Mr. Pardee was a founder and board member of the Dow Chemical Company. Before her death from breast cancer in 1944 at the age of 59, Elsa directed that $1 million in Dow stock be devoted to the "control and cure of cancer." The Elsa U. Pardee Foundation was formed in memory of Elsa by the family she left behind.

The FY20 LCRP Idea Development Award mechanism promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation. This award supports conceptually innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress toward eradicating deaths and suffering from lung cancer. Applications should include a well- formulated, testable hypothesis based on strong scientific rationale. Submissions from and partnerships with investigators at Department of Defense (DoD) military treatment facilities and laboratories, and Department of Veterans Affairs (VA) medical centers and research laboratories are strongly encouraged.

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for projects to expand, improve, or transform the utility of mammalian cancer and tumor models for translational research. With this FOA, the NCI intends to encourage submission of projects devoted to demonstrating that mammalian models or their derivatives used for translational research are robust representations of human biology, are appropriate to test questions of clinical importance, and provide reliable information for patients' benefit. These practical goals contrast with the goals of many mechanistic, NCI-supported R01 projects that employ mammals, or develop and use mammalian cancer models, transplantation tumor models, or models derived from mammalian or human tissues or cells for hypothesis-testing, non-clinical research. Among many other possible endeavors, applicants in response to this FOA could propose demonstrations of how to overcome translational deficiencies of mammalian oncology models, define new uses of mammalian models or their genetics for unexplored translational challenges, advance standard practices for use of translational models, test approaches to validate and credential models, or challenge current practices for how models are used translationally

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) encourages grant applications for support of the core functions of Cancer Epidemiology Cohorts (CECs), as well as methodological research. This FOA is intended to support maintenance of existing CECs infrastructure and resource sharing with broader scientific communities.

The FY20 LCRP Investigator-Initiated Translational Research Award mechanism supports translational research that will develop promising ideas in lung cancer into clinical applications. Translational research may be defined as an integration of basic science and clinical observations. Observations that drive a research idea may originate from a laboratory discovery, population-based studies, or a clinician's firsthand knowledge of patient care. The ultimate goal of translational research is to move a concept or observation forward into clinical application. However, Principal Investigators (PIs) should not view translational research as a one-way continuum from bench to bedside. The research plan must involve a reciprocal flow of ideas and information between basic and clinical science.